Keros Therapeutics, Inc. KROS
9.54 USD +0.21 (+2.25%)
At closeNov 11, 2026, 4:26 PM EST
9.54 0.00 0.00%
After hours · Nov 11, 4:26 PM ET
9.23 Day range 9.73
8.98 52-week range 22.55
- YTD
- -53.14%
- 1 year
- -43.55%
News
zacks.com Down 21% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround Keros Therapeutics (KROS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings…
zacks.com Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of a loss of $0.96 per share. This compares to a loss of $0.18 per share a…
marketbeat.com Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage Keros Therapeutics NASDAQ: KROS is repositioning its pipeline around rinvatercept, a skeletal-muscle regeneration candidate being developed for neuromuscular diseases, while its partnered program…
defenseworld.net Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS) Keros Therapeutics (NASDAQ: KROS - Get Free Report) and Upstream Bio (NASDAQ: UPB - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two…
zacks.com KROS Begins Dosing in Phase II Study With Rinvatercept in DMD Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
benzinga.com Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis ("MF") and anemia on concurrent…
globenewswire.com Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel…
benzinga.com Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with…
globenewswire.com Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel…
benzinga.com Keros Therapeutics Reveals $5M Share Repurchase Authorization Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of
globenewswire.com Keros Therapeutics Announces $5 Million Share Repurchase Authorization LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and…
zacks.com Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?
defenseworld.net Hsbc Holdings PLC Makes New $761,000 Investment in Keros Therapeutics, Inc. $KROS Hsbc Holdings PLC acquired a new position in Keros Therapeutics, Inc. (NASDAQ: KROS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The…
zacks.com Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
zacks.com KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
defenseworld.net Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP Dimensional Fund Advisors LP lifted its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 453.9% during the undefined quarter, according to the company in its most recent Form 13F filing with…
defenseworld.net Keros Therapeutics, Inc. $KROS Shares Acquired by Empowered Funds LLC Empowered Funds LLC raised its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 142.2% during the first quarter, according to the company in its most recent filing with the Securities and…
zacks.com KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.- benzinga.com Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18 Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.
benzinga.com Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.34) by 8.21 percent. This is a 90.79 percent decrease over losses of…
globenewswire.com Keros Therapeutics Reports Second Quarter 2026 Financial Results LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and…
benzinga.com Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of elritercept versus epoetin alfa for the treatment of anemia due to very low, low, or…
globenewswire.com Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel…
zacks.com New Strong Sell Stocks for July 30th ITRG, BEEM and KROS have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2026.
globenewswire.com Keros Therapeutics Appoints Anne Prener to its Board of Directors LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and…
seekingalpha.com Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
benzinga.com Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which missed the analyst consensus estimate of $(1.02) by 18.63 percent. This is a 133.43 percent decrease over…- benzinga.com Keros Therapeutics Presents Additional Data From Its Phase 1 Clinical Study Of Rinvatercept In Health Volunteers At 2026 Muscular Dystrophy Association Clinical & Scientific Conference Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of…
- benzinga.com Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20 Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $23 to $20.
- benzinga.com CORRECTION: Keros Therapeutics Q4 EPS $(0.86) Misses $(0.60) Estimate, Sales $385.000K Miss $2.757M Estimate Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.60) by 42.62 percent. This is a 24.56 percent increase over losses…
benzinga.com Keros Therapeutics: Q4 Earnings Insights 
benzinga.com Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are all itching for a deal.
benzinga.com PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Nasdaq Down 50 Points; US Initial Jobless Claims Rise
benzinga.com Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - benzinga.com Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at…
- benzinga.com Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 386 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022 Upgrades- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 216 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 951 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 422 stocks made new 52-week lows.